Oncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022
August 01 2022 - 5:00AM
Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics
company with the mission to improve patient outcomes by providing
personalized insights that inform critical decisions throughout the
patient care journey, today announced the appointment of John Peter
(JP) Gutfreund as an independent member of its board of directors,
effective July 28, 2022.
“We welcome JP to our Board of Directors at what we believe to
be an important time in the life of Oncocyte, as we anticipate
bringing three major products through reimbursement and to market
over the next four quarters,” said Ron Andrews, CEO of Oncocyte.
“He brings a wealth of financial experience to our team, and his
expertise will be immensely valuable as we look to balance our need
to manage our cash while effectively executing on the growth phase
ahead."
Since October 2019, Mr. Gutfreund has served as Managing Partner
of Halle Capital Management, a growth oriented private equity firm
focused on middle-market companies in the healthcare, consumer, and
business services sectors. Mr. Gutfreund serves on the board of
several Halle portfolio companies. Mr. Gutfreund is a trustee at
Montefiore Health System, a New York based academic health system,
where he serves as a member of the investment committee. Prior to
joining Halle Capital Management, Mr. Gutfreund was the Director of
Research at Glenview Capital Management from March 2013 to
September 2019. Mr. Gutfreund worked in Investment Banking earlier
in his career and holds a BA from New York University.
“I am thrilled to be joining the Oncocyte Board of Directors,"
said Mr. Gutfreund. "Oncocyte is on an exciting path, with multiple
products in the pipeline, and I look forward to working with the
Board to support management's vision for shareholder value
creation.”
About OncocyteOncocyte is a precision
diagnostics company with a mission to improve patient outcomes by
providing personalized insights that inform critical decisions
throughout the patient care journey.
Through its proprietary tests and pharmaceutical services
business, the Company aims to help save lives by accelerating the
diagnosis of cancer and advancing cancer care. The Company’s tests
are designed to help provide clarity and confidence to physicians
and their patients at every stage. DetermaRx™ identifies
early-stage lung cancer patients who are at high risk for cancer
recurrence and who may benefit from adjuvant chemotherapy.
DetermaIO™ is a gene expression test that assesses the tumor
microenvironment to predict response to immunotherapies. The
Company’s pipeline of tests in development also includes
DetermaTx™, which will assess mutational status of a tumor,
DetermaCNI™, a blood-based monitoring test, DetermaMx™, a long-term
recurrence monitoring test, and VitaGraft™, a blood-based solid
organ transplantation monitoring test. In addition, Oncocyte’s
pharmaceutical services provide companies that are developing new
cancer treatments a full suite of molecular testing services to
support the drug development process.DetermaRx™, DetermaIO™,
DetermaTx™, DetermaCNI™, DetermaMx™ and VitaGraft™ are trademarks
of Oncocyte Corporation.
Forward-Looking StatementsAny statements that
are not historical fact (including, but not limited to statements
that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects,” “estimates,” “may,” and similar
expressions) are forward-looking statements. These statements
include those pertaining to, among other things, the anticipation
that the Company will bring three major products through
reimbursement and to market over the next four quarters, the
expected growth phase ahead and Oncocyte’s pipeline, and other
statements about the future expectations, beliefs, goals, plans, or
prospects expressed by management. Forward-looking statements
involve risks and uncertainties, including, without limitation, the
potential impact of COVID-19 on Oncocyte or its
subsidiaries’ financial and operational results, risks inherent in
the development and/or commercialization of diagnostic tests or
products, uncertainty in the results of clinical trials or
regulatory approvals, the capacity of Oncocyte’s third-party
supplied blood sample analytic system to provide consistent and
precise analytic results on a commercial scale, potential
interruptions to supply chains, the need and ability to obtain
future capital, maintenance of intellectual property rights in all
applicable jurisdictions, obligations to third parties with respect
to licensed or acquired technology and products, the need to obtain
third party reimbursement for patients’ use of any diagnostic
tests Oncocyte or its subsidiaries commercialize in
applicable jurisdictions, and risks inherent in strategic
transactions such as the potential failure to realize anticipated
benefits, legal, regulatory or political changes in the applicable
jurisdictions, accounting and quality controls, potential greater
than estimated allocations of resources to develop and
commercialize technologies, or potential failure to maintain any
laboratory accreditation or certification. Actual results may
differ materially from the results anticipated in these
forward-looking statements and accordingly such statements should
be evaluated together with the many uncertainties that affect the
business of Oncocyte, particularly those mentioned in the
“Risk Factors” and other cautionary statements found in
Oncocyte’s Securities and Exchange Commission (SEC)
filings, which are available from the SEC’s website. You are
cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date on which they were
made. Oncocyte undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made, except as required by
law.
Investor & Media ContactCaroline CornerICR
WestwickeTel: 415.202.5678caroline.corner@westwicke.com
Oncocyte (NASDAQ:OCX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncocyte (NASDAQ:OCX)
Historical Stock Chart
From Apr 2023 to Apr 2024